Newborn screening for rare diseases: expanding the paradigm in the genomic era

Area of Science:

• Genomics and Public Health
• Rare Disease Diagnosis
• Bioethics

Background:

• Newborn screening (NBS) traditionally detects a few congenital disorders, preventing severe health issues.
• Genomic technologies like next-generation sequencing (NGS) and whole-exome sequencing (WES) are expanding NBS to include rare diseases (RDs).
• Integrating RDs into NBS presents challenges in condition selection, test validation, and follow-up care, alongside ethical considerations.

Purpose of the Study:

• To review the evolution of NBS from biochemical methods to genomic approaches.
• To discuss the complexities and ethical tensions in expanding NBS for rare diseases.
• To highlight the need for international harmonization and stakeholder engagement.

Main Methods:

• Literature review of NBS evolution.
• Analysis of challenges in integrating rare diseases into NBS panels.
• Discussion of ethical considerations and policy implications.

Main Results:

• Genomic NBS (gNBS) offers transformative potential for early diagnosis and intervention in rare diseases.
• Successful gNBS requires clear inclusion criteria, validated diagnostics, and sustainable follow-up.
• Evolving genomic tools necessitate agile policies, secure data infrastructure, and attention to consent, privacy, and equity.

Conclusions:

• Expanding NBS to include RDs can significantly improve patient outcomes through early detection and timely treatment.
• Effective implementation of genomic NBS hinges on evidence-based criteria, validated diagnostics, and comprehensive follow-up systems.
• International collaboration and ethical considerations are crucial for the responsible integration of advanced genomic technologies into NBS programs.